Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on April 28, 2025, to report its first quarter 2025 financial and operating results. The key details of these results are provided in a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for the specific financial performance and operational achievements during the quarter ended March 31, 2025. The filing itself primarily serves as a notification of the release of this information, rather than containing extensive new disclosures within the 8-K document itself.
Key Highlights
- 1Regeneron announced its Q1 2025 financial and operating results on April 29, 2025.
- 2The detailed results are contained in a press release furnished as Exhibit 99.1.
- 3Investors should consult the referenced press release for specific financial metrics and operational performance updates.
- 4The 8-K filing serves as the official notification of the earnings release.
- 5No new material information is presented directly within the 8-K; it directs readers to the press release.
- 6The filing covers the quarter ended March 31, 2025.